We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Test Predicts Breast Cancer Relapse

By LabMedica International staff writers
Posted on 17 Feb 2011
Print article
A gene signature has been discovered that can accurately predict which breast cancer patients are at risk of relapse, thereby sparing those who are not at risk from the burdens associated with unnecessary treatment.

The test analyzes two sets of 29 genes from breast cancer-tumor samples. One set of genes is responsible for rampant neoplasia, which is the very fundamental nature of cancer, and the second set involves genetic instability. When the test results show high expressions of both sets of these genes, the patient would be at a high risk of a relapse.
Scientists at McGill University,(Montreal, QC, Canada), and their US colleagues, used a variety of molecular biology techniques to examine in 12 publicly available gene expression datasets comprising a total of 2,481 patients with breast cancer. The test is reported to be superior to an existing test, and has the potential to spare women at a very low risk of relapse of breast cancer from undergoing toxic chemotherapy.

Clinicians have been faced with the problem that breast cancer cannot be treated with a one-size-fits-all approach. Some cancers respond to specific treatments while others do not. Close to 50% of breast cancer patients belong to a group defined as "estrogen receptor positive/lymph node negative (ER+/LR-)", who are at low risk of relapse. The majority of patients in this group may not require any treatment beyond the surgical removal of their tumor, while a small minority should receive additional treatment.

Alain Nepveu, PhD, coauthor of the study, said, "The added information provided by our test would enable oncologists to identify those at very low risk of relapse, for whom the risk-benefit ratio might be in favor of withholding chemotherapy, and to identify patients in this low-risk group who would benefit from more aggressive treatments". The study was published on February 1, 2011, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:
McGill University



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
H.pylori DNA Extraction Kit
Savvygen Stool NA Extraction Kit
New
Clostridium Difficile Assay
Revogene C. Difficile

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.